Related coverage linked through entity extraction aliases.
Jul 30, 2026
In 2025, China's NMPA approved 289 new drug applications, including traditional Chinese medicines. A study reveals critical methodological gaps in clinical trials of herbal therapies, while a review highlights the potential of nanoformulations for renal fibrosis.
Jul 10, 2026
Phase III data show deramiocel slowed upper limb decline by 54% in Duchenne muscular dystrophy. The FDA is re-evaluating the BLA with HOPE-3 results, with a submission of the clinical study report expected in February 2026.
Mar 21, 2026
Deupirfenidone, a deuterated form of pirfenidone, is set to be tested in a phase 3 trial this year after successful phase 2b results. The FDA and European Commission have granted orphan drug designation to support its late-stage development.
